Home/GenomeFrontier Therapeutics/Marcus J. Calkins, PhD
MJ

Marcus J. Calkins, PhD

Director, Scientific Communication

GenomeFrontier Therapeutics

Therapeutic Areas

GenomeFrontier Therapeutics Pipeline

DrugIndicationPhase
GF-CART01B cell malignanciesPreclinical
GF-CART02Multiple myelomaPreclinical
GF-CART03Solid tumorsPreclinical